

Author Index Volume 34 (2013)

The issue number is given in front of the pagination

- AbdRaboh, N.R., H.H. Shehata, M.B. Ahmed and F.A. Bayoumi, *HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer* (6) 407–417
- Affandi, J.S., M. Kumar, U. Agarwal, S. Singh and P. Price, *The search for a genetic factor associating with immune restoration disease in HIV patients co-infected with *Mycobacterium tuberculosis** (6) 445–449
- Agarwal, U., see Affandi, J.S. (6) 445–449
- Agostini, M., C. Bedin, M.V. Enzo, L. Molin, P. Traldi, E. D'Angelo, E. Maschietto, R. Serraglia, E. Ragazzi, L. Prevedello, M. Foletto and D. Nitti, *Multivariate analysis approach to the serum peptide profile of morbidly obese patients* (4) 269–278
- Ahmed, M.B., see AbdRaboh, N.R. (6) 407–417
- Ajwani, H., see Kathariya, R. (3) 143–151
- Akhondi, M.M., see Lakpour, N. (3) 205–210
- Al Robaee, A.A., see Salama, R.H.M. (1) 33–39
- AlFadhli, S., *Influence of endothelial nitric oxide synthase gene intron-4 27bp repeat polymorphism on its expression in autoimmune diseases* (5) 349–356
- Ali, K., see Baig, R.M. (2) 71–80
- Al-Shobaili, H.A., see Salama, R.H.M. (1) 33–39
- Altieri, P., see Ghigliotti, G. (2) 131–142
- Alzolibani, A.A., see Salama, R.H.M. (1) 33–39
- Amirjannati, N., see Lakpour, N. (3) 205–210
- Anastasiou, G., see Zigra, A.-M. (6) 431–436
- Aristi, G., see Palma, I. (6) 419–424
- Arroyo-Pardo, E., see Baeza-Richer, C. (2) 121–129
- Ausch, C., see Buxhofer-Ausch, V. (3) 171–177
- Aydoğdu, M., G. Gürsel, B. Sancak, S. Yeni, G. Sarı, S. Taşyürek, M. Türk, S. Yüksel, M. Şnez and T.N. Özis, *The use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and Cystatin C in early diagnosis of septic acute kidney injury in critically ill patients* (4) 237–246
- Babu, S.D., see Benson, C.S. (6) 395–405
- Baccar, A., I. Ferchichi, W. Troudi, R. Marrakchi, N. Ben Hmida, S. Jebini, K. Mrad, K. Ben Romdhane and A. Benammar Elgaaied, *CD99 and HLA-II immunostaining in breast cancer tissue and their correlation with lymph node metastasis* (5) 363–371
- Baccar, A., see Ferchichi, I. (2) 63–69
- Badr, S., see Eissa, S. (1) 57–62
- Baeza-Richer, C., R. Blanco-Rojo, A.M. López-Parra, A. Brichs, S. Bertoncini, A.M. Pérez-Granados, A. Buil, J.M. Soria, E. Arroyo-Pardo and M.P. Vaquero, *Identification of a novel quantitative trait nucleotide related to iron status in a calcium channel gene* (2) 121–129
- Baig, R.M., I. Mahjabeen, M. Sabir, N. Masood, K. Ali, F.A. Malik and M.A. Kayani, *Mutational spectrum of Gelsolin and its down regulation is associated with breast cancer* (2) 71–80
- Barisione, C., see Ghigliotti, G. (2) 131–142
- Bayoumi, F.A., see AbdRaboh, N.R. (6) 407–417
- Bedin, C., see Agostini, M. (4) 269–278
- Beltrão, E.I.C., see de Melo Rêgo, M.J.B. (5) 373–377
- Ben Ammar El Gaaied, A., see Ferchichi, I. (2) 63–69
- Ben Hmida, N., see Baccar, A. (5) 363–371
- Ben Romdhane, K., see Baccar, A. (5) 363–371
- Ben Romdhane, K., see Ferchichi, I. (2) 63–69
- Benammar Elgaaied, A., see Baccar, A. (5) 363–371
- Benson, C.S., S.D. Babu, S. Radhakrishna, N. Selvamurugan and B.R. Sankar, *Expression of matrix metalloproteinases in human breast cancer tissues* (6) 395–405
- Berdeli, A., see Nalbantoglu, S. (1) 23–32
- Bernstein, H.-G., see Kanakis, D. (2) 81–91
- Berretta, M., see Malaguarnera, G. (4) 219–228
- Bertino, G., see Malaguarnera, G. (4) 219–228
- Bertoncini, S., see Baeza-Richer, C. (2) 121–129
- Binaschi, M., see Bressan, A. (4) 257–267
- Blanco-Prieto, S., see Sánchez-Otero, N. (6) 425–430

- Blanco-Rojo, R., see Baeza-Richer, C. (2) 121–129
- Bogerts, B., see Kanakis, D. (2) 81–91
- Boquett, J.A., A.P.C. Brandalize, L.R. Fraga and L. Schuler-Faccini, Maternal SNPs in the p53 pathway: Risk factors for trisomy 21? (1) 41–49
- Botana-Rial, M.I., see Sánchez-Otero, N. (6) 425–430
- Bozzo, F., see Bressan, A. (4) 257–267
- Brandalize, A.P.C., see Boquett, J.A. (1) 41–49
- Bressan, A., F. Bozzo, C.A. Maggi and M. Binaschi, OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain (4) 257–267
- Brichs, A., see Baeza-Richer, C. (2) 121–129
- Brunelli, C., see Ghigliotti, G. (2) 131–142
- Brzozowska-Czarnek, A., see Kleczyński, P. (3) 199–204
- Buil, A., see Baeza-Richer, C. (2) 121–129
- Bukowska, A., see Kanakis, D. (2) 81–91
- Buxhofer-Ausch, V., C. Ausch, R. Zeillinger, C. Oberkanins, N. Dandachi, A. Reiner-Concin and G. Kriegshäuser, Duplex reverse-hybridization assay for the simultaneous detection of *KRAS/BRAF* mutations in FFPE-extracted genomic DNA from colorectal cancer specimens (3) 171–177
- Cai, A., D. Zheng, R. Qiu, W. Mai and Y. Zhou, Lipoprotein-associated phospholipase A2 (Lp-PLA)₂: A novel and promising biomarker for cardiovascular risks assessment (5) 323–331
- Cai, Q., see Wu, S.-H. (4) 279–293
- Cecen, O., see Inanir, A. (1) 17–22
- Celec, P., see Kamodyová, N. (5) 313–321
- Celec, P., see Tóthová, L. (1) 9–15
- Celecová, V., see Tóthová, L. (1) 9–15
- Chan, M.H.-M., see Luk, C.C.-W. (3) 179–185
- Chen, T.-C., see Lee, C.-T. (4) 229–235
- Chiu, T.T.-Y., see Lee, C.-T. (4) 229–235
- Chow, K.-M., see Luk, C.C.-W. (3) 179–185
- Chow, W.-H., see Wu, S.-H. (4) 279–293
- Chua, S., see Lee, C.-T. (4) 229–235
- Contreras, A., see Palma, I. (6) 419–424
- Cordeiro, M.F., see de Melo Rêgo, M.J.B. (5) 373–377
- Cremet, J.Y., see Ferchichi, I. (2) 63–69
- Cui, Y.-Q., see Jiang, Z.-L. (5) 295–304
- Cybulski, K., see Korzeniecka-Kozerska, A. (5) 357–362
- Dandachi, N., see Buxhofer-Ausch, V. (3) 171–177
- D'Angelo, E., see Agostini, M. (4) 269–278
- de Carvalho Junior, L.B., see de Melo Rêgo, M.J.B. (5) 373–377
- de la Cadena, M.P., see Sánchez-Otero, N. (6) 425–430
- de Lima Bezerra Cavalcanti, C., see de Melo Rêgo, M.J.B. (5) 373–377
- de Melo Rêgo, M.J.B., M.F. Cordeiro, C. de Lima Bezerra Cavalcanti, L.B. de Carvalho Junior and E.I.C. Beltrão, Immunohistochemiluminescence detection: A quantitative tool in breast cancer HER-2 status evaluation (5) 373–377
- Dietzmann, K., see Kanakis, D. (2) 81–91
- Dobrowolny, H., see Kanakis, D. (2) 81–91
- Dominguez, C., see Palma, I. (6) 419–424
- Dubiel, J.S., see Kleczyński, P. (3) 199–204
- Dudek, D., see Kleczyński, P. (3) 199–204
- Dziewierz, A., see Kleczyński, P. (3) 199–204
- Egarter, C., see Kuessel, L. (1) 51–56
- Eissa, S., S. Badr, S.A. Elhamid, A.S. Helmy, M. Nour and M. Esmat, The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine (1) 57–62
- Elhamid, S.A., see Eissa, S. (1) 57–62
- Enzo, M.V., see Agostini, M. (4) 269–278
- Esmat, M., see Eissa, S. (1) 57–62
- Espino-Silva, P.K., see Mar-Aguilar, F. (3) 163–169
- Fabbi, P., see Ghigliotti, G. (2) 131–142
- Fang, F., see Feng, G. (2) 105–111
- Farivar, S., see Lakpour, N. (3) 205–210
- Feng, G., X. Ye, F. Fang, C. Pu, H. Huang and G. Li, Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma (2) 105–111
- Ferchichi, I., S. Sassi Hannachi, A. Baccar, R. Marakchi Triki, J.Y. Cremet, K. Ben Romdhane, C. Prigent and A. Ben Ammar El Gaaied, Assessment of Aurora A kinase expression in breast cancer: A tool for early diagnosis? (2) 63–69
- Ferchichi, I., see Baccar, A. (5) 363–371
- Fernández-Villar, A., see Sánchez-Otero, N. (6) 425–430
- Foletto, M., see Agostini, M. (4) 269–278
- Fraga, L.R., see Boquett, J.A. (1) 41–49
- Fu, Z.-C., see Jiang, Z.-L. (5) 295–304
- Gao, R., see Jiang, Z.-L. (5) 295–304
- Gao, Y.-T., see Wu, S.-H. (4) 279–293
- Garibaldi, S., see Ghigliotti, G. (2) 131–142
- Garibay, N., see Palma, I. (6) 419–424

- Ghigliotti, G., C. Barisione, S. Garibaldi, C. Brunelli, D. Palmieri, G. Spinella, B. Pane, P. Spallarossa, P. Altieri, P. Fabbi, G. Sambuceti and D. Palombo, CD16⁺ monocyte subsets are increased in large abdominal aortic aneurysms and are differentially related with circulating and cell-associated biochemical and inflammatory biomarkers (2) 131–142
- Gialeraki, A., see Zigra, A.-M. (6) 431–436
- Giordano, M., see Malaguarnera, G. (4) 219–228
- Glavač, D., see Hrašovec, S. (2) 93–104
- Gonçalves, G., see Palavra, F. (5) 341–348
- Grimm, C., see Kuessel, L. (1) 51–56
- Guan, C.-C., see Jiang, Z.-L. (5) 295–304
- Gujar, D., see Kathariya, R. (3) 143–151
- Guo, Y.-L., see Qing, P. (5) 333–339
- Gürsel, G., see Aydoğdu, M. (4) 237–246
- Haneda, T., see Yamamoto, M. (3) 153–161
- Hashemi, S.B., see Lakpour, N. (3) 205–210
- Haslinger, P., see Kuessel, L. (1) 51–56
- Hauptman, N., see Hrašovec, S. (2) 93–104
- He, J., F. Zhang, Y. Wu, W. Zhang, X. Zhu, X. He, Y. Zhao, W. Zhang and Y. Zhao, Prognostic role of microRNA-155 in various carcinomas: Results from a meta-analysis (6) 379–386
- He, X., see He, J. (6) 379–386
- Heidari-Vala, H., see Lakpour, N. (3) 205–210
- Heinze, G., see Kuessel, L. (1) 51–56
- Helmy, A.S., see Eissa, S. (1) 57–62
- Hrašovec, S., N. Hauptman, D. Glavač, F. Jelenc and M. Ravnik-Glavač, *TMEM25* is a candidate biomarker methylated and down-regulated in colorectal cancer (2) 93–104
- Hsu, C.-Y., see Lee, C.-T. (4) 229–235
- Hua, C.-H., see Li, Y.-F. (4) 247–255
- Huang, H., see Feng, G. (2) 105–111
- Huang, R.-J., see Liu, C.-S. (3) 187–197
- Huang, Y.-T., see Li, Y.-F. (4) 247–255
- Imai, Y., see Yamamoto, M. (3) 153–161
- Inanir, A., S. Yigit, S. Tural, O. Cecen and E. Yildirim, *MTHFR* gene C677T mutation and *ACE* gene I/D polymorphism in Turkish patients with osteoarthritis (1) 17–22
- Jain, H., see Kathariya, R. (3) 143–151
- Jang, H.C., see Kim, S.E. (3) 211–218
- Jang, M.O., see Kim, S.E. (3) 211–218
- Jebini, S., see Bacchar, A. (5) 363–371
- Jelenc, F., see Hrašovec, S. (2) 93–104
- Ji, B.-T., see Wu, S.-H. (4) 279–293
- Jia, Y.-J., see Qing, P. (5) 333–339
- Jiang, L.-X., see Qing, P. (5) 333–339
- Jiang, Z.-L., Y.-Q. Cui, R. Gao, Y. Li, Z.-C. Fu, B. Zhang and C.-C. Guan, Study of TNF- α , IL-1 β and LPS levels in the gingival crevicular fluid of a rat model of diabetes mellitus and periodontitis (5) 295–304
- Jung, S.I., see Kim, S.E. (3) 211–218
- Kamodyová, N., L. Tóthová and P. Celec, Salivary markers of oxidative stress and antioxidant status: Influence of external factors (5) 313–321
- Kanakis, D., U. Lendeckel, P. Theodosiou, H. Dobrowolny, C. Mawrin, G. Keilhoff, A. Bukowska, K. Dietzmann, B. Bogerts and H.-G. Bernstein, ADAM 12: A putative marker of oligodendrogliomas? (2) 81–91
- Kang, S.J., see Kim, S.E. (3) 211–218
- Kathariya, R., H. Jain, D. Gujar, A. Singh, H. Ajwani and D. Mandhyan, Pentraxins as key disease markers for periodontal diagnosis (3) 143–151
- Kathariya, R., see Sukhtankar, L. (5) 305–311
- Kayani, M.A., see Baig, R.M. (2) 71–80
- Keilhoff, G., see Kanakis, D. (2) 81–91
- Kim, H.J., see Lee, I.S. (2) 113–120
- Kim, H.S., see Lee, I.S. (2) 113–120
- Kim, S.E., U.J. Kim, M.O. Jang, S.J. Kang, H.C. Jang, S.I. Jung, S.S. Lee and K.H. Park, Diagnostic use of serum ferritin levels to differentiate infectious and noninfectious diseases in patients with fever of unknown origin (3) 211–218
- Kim, U.J., see Kim, S.E. (3) 211–218
- Kleczyński, P., J. Legutko, T. Rakowski, A. Dziewierz, Z. Siudak, J. Zdzienicka, A. Brzozowska-Czarnek, A. Surdacki, J.S. Dubiel and D. Dudek, Predictive utility of NT-pro BNP for infarct size and left ventricle function after acute myocardial infarction in long-term follow-up (3) 199–204
- Knöfler, M., see Kuessel, L. (1) 51–56
- Korzeniecka-Kozerska, A., A. Wasilewska, E. Tenderenda, A. Sulik and K. Cybulski, Urinary MMP-9/NGAL ratio as a potential marker of FSGS in nephrotic children (5) 357–362
- Kriegshäuser, G., see Buxhofer-Ausch, V. (3) 171–177
- Ku, B.J., see Lee, I.S. (2) 113–120
- Kuessel, L., C. Grimm, M. Knöfler, P. Haslinger, H. Leipold, G. Heinze, C. Egarter and M. Schmid, Common oxytocin receptor gene polymorphisms and the risk for preterm birth (1) 51–56
- Kulloli, A., see Sukhtankar, L. (5) 305–311

- Kumar, M., see Affandi, J.S. (6) 445–449
- Kuo, C.-C., see Lee, C.-T. (4) 229–235
- Kwan, B.C.-H., see Luk, C.C.-W. (3) 179–185
- Kwok, J.S.-S., see Luk, C.C.-W. (3) 179–185
- Lai, F.M.-M., see Luk, C.C.-W. (3) 179–185
- Lai, K.-B., see Luk, C.C.-W. (3) 179–185
- Lakpour, N., A. Mirfeizollahi, S. Farivar, M.M. Akhondi, S.B. Hashemi, N. Amirjannati, H. Heidari-Vala and M.R. Sadeghi, The association of seminal plasma antioxidant levels and sperm chromatin status with genetic variants of *GSTM1* and *GSTP1* (Ile105Val and Ala114Val) in infertile men with oligoasthenoteratozoospermia (3) 205–210
- Lee, C.-T., S. Chua, C.-Y. Hsu, Y.-C. Tsai, H.-Y. Ng, C.-C. Kuo, C.-H. Wu, T.-C. Chen, T.T.-Y. Chiu and Y.-T. Lee, Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients (4) 229–235
- Lee, I.S., J.H. Lee, H.J. Kim, J.M. Lee, S.K. Lee, H.S. Kim, J.M. Lee, K.S. Park and B.J. Ku, Novel *ERBB* receptor feedback inhibitor 1 (*ERRF1*) + 808 T/G polymorphism confers protective effect on diabetic nephropathy in a Korean population (2) 113–120
- Lee, J.H., see Lee, I.S. (2) 113–120
- Lee, J.M., see Lee, I.S. (2) 113–120
- Lee, J.M., see Lee, I.S. (2) 113–120
- Lee, S.K., see Lee, I.S. (2) 113–120
- Lee, S.S., see Kim, S.E. (3) 211–218
- Lee, Y.-T., see Lee, C.-T. (4) 229–235
- Legutko, J., see Kleczyński, P. (3) 199–204
- Leipold, H., see Kuessel, L. (1) 51–56
- Lendeckel, U., see Kanakis, D. (2) 81–91
- Li, G., see Feng, G. (2) 105–111
- Li, H.-L., see Wu, S.-H. (4) 279–293
- Li, J.-J., see Qing, P. (5) 333–339
- Li, P.K.-T., see Luk, C.C.-W. (3) 179–185
- Li, Y., see Jiang, Z.-L. (5) 295–304
- Li, Y.-F., F.-C. Sung, M.-H. Tsai, C.-H. Hua, C.-S. Liu, Y.-T. Huang and C.-C. Yeh, Interactions between cigarette smoking and polymorphisms of xenobiotic-metabolizing genes: The risk of oral leukoplakia (4) 247–255
- Lin, C.-C., see Liu, C.-S. (3) 187–197
- Liu, C.-S., R.-J. Huang, F.-C. Sung, C.-C. Lin and C.-C. Yeh, Association between endothelial nitric oxide synthase polymorphisms and risk of metabolic syndrome (3) 187–197
- Liu, C.-S., see Li, Y.-F. (4) 247–255
- Liu, J., see Qing, P. (5) 333–339
- López-Parra, A.M., see Baeza-Richer, C. (2) 121–129
- Luk, C.C.-W., K.-M. Chow, J.S.-S. Kwok, B.C.-H. Kwan, M.H.-M. Chan, K.-B. Lai, F.M.-M. Lai, G. Wang, P.K.-T. Li and C.-C. Szeto, Urinary biomarkers for the prediction of reversibility in acute-on-chronic renal failure (3) 179–185
- Luo, S.-H., see Qing, P. (5) 333–339
- Ma, F.-L., see Qing, P. (5) 333–339
- Maggi, C.A., see Bressan, A. (4) 257–267
- Mahjabeen, I., see Baig, R.M. (2) 71–80
- Mahjoubi, F., see Taheri, M. (6) 387–393
- Mai, W., see Cai, A. (5) 323–331
- Malagón-Santiago, I., see Mar-Aguilar, F. (3) 163–169
- Malaguarnera, G., I. Paladina, M. Giordano, M. Malaguarnera, G. Bertino and M. Berretta, Serum markers of intrahepatic cholangiocarcinoma (4) 219–228
- Malaguarnera, M., see Malaguarnera, G. (4) 219–228
- Malik, F.A., see Baig, R.M. (2) 71–80
- Mandhyan, D., see Kathariya, R. (3) 143–151
- Marado, D., see Palavra, F. (5) 341–348
- Mar-Aguilar, F., J.A. Mendoza-Ramírez, I. Malagón-Santiago, P.K. Espino-Silva, S.K. Santuario-Facio, P. Ruiz-Flores, C. Rodríguez-Padilla and D. Reséndez-Pérez, Serum circulating microRNA profiling for identification of potential breast cancer biomarkers (3) 163–169
- Marrakchi Triki, R., see Ferchichi, I. (2) 63–69
- Marrakchi, R., see Baccar, A. (5) 363–371
- Mascarenhas-Melo, F., see Palavra, F. (5) 341–348
- Maschietto, E., see Agostini, M. (4) 269–278
- Masood, N., see Baig, R.M. (2) 71–80
- Mawrin, C., see Kanakis, D. (2) 81–91
- Mendoza-Ramírez, J.A., see Mar-Aguilar, F. (3) 163–169
- Merkouri, E., see Zigra, A.-M. (6) 431–436
- Milne, G., see Wu, S.-H. (4) 279–293
- Mir, S., see Nalbantoglu, S. (1) 23–32
- Mirfeizollahi, A., see Lakpour, N. (3) 205–210
- Molin, L., see Agostini, M. (4) 269–278
- Mrad, K., see Baccar, A. (5) 363–371
- Nalbantoglu, S., Y. Tabel, S. Mir, E. Serdaroğlu and A. Berdeli, Association between RAS gene polymorphisms (*ACE I/D*, *AGT M235T*) and Henoch-Schönlein purpura in a Turkish population (1) 23–32
- Ng, H.-Y., see Lee, C.-T. (4) 229–235
- Nitti, D., see Agostini, M. (4) 269–278
- Nour, M., see Eissa, S. (1) 57–62

- Nunes, C.C., see Palavra, F. (5) 341–348
- Oberkanins, C., see Buxhofer-Ausch, V. (3) 171–177
- Özis, T.N., see Aydoğdu, M. (4) 237–246
- Paladina, I., see Malaguarnera, G. (4) 219–228
- Palavra, F., D. Marado, F. Mascarenhas-Melo, J. Sereno, E. Teixeira-Lemos, C.C. Nunes, G. Gonçalves, F. Teixeira and F. Reis, New markers of early cardiovascular risk in multiple sclerosis patients: Oxidized-LDL correlates with clinical staging (5) 341–348
- Palma, I., N. Garibay, R. Pena-Yolanda, A. Contreras, A. Raya, C. Dominguez, M. Romero, G. Aristi and G. Queipo, Utility of OCT3/4, TSPY and β -catenin as biological markers for gonadoblastoma formation and malignant germ cell tumor development in dysgenetic gonads (6) 419–424
- Palmieri, D., see Ghigliotti, G. (2) 131–142
- Palombo, D., see Ghigliotti, G. (2) 131–142
- Pane, B., see Ghigliotti, G. (2) 131–142
- Park, K.H., see Kim, S.E. (3) 211–218
- Park, K.S., see Lee, I.S. (2) 113–120
- Pena-Yolanda, R., see Palma, I. (6) 419–424
- Pérez-Granados, A.M., see Baeza-Richer, C. (2) 121–129
- Pradeep, A.R., see Shivaprasad, B.M. (1) 1–7
- Prevedello, L., see Agostini, M. (4) 269–278
- Price, P., see Affandi, J.S. (6) 445–449
- Prigent, C., see Ferchichi, I. (2) 63–69
- Pu, C., see Feng, G. (2) 105–111
- Qing, P., S.-H. Luo, Y.-L. Guo, J. Liu, R.-X. Xu, C.-G. Zhu, Y.-J. Jia, F.-L. Ma, N.-Q. Wu, L.-X. Jiang and J.-J. Li, Evaluation of red blood cell distribution width in patients with cardiac syndrome X (5) 333–339
- Qiu, R., see Cai, A. (5) 323–331
- Queipo, G., see Palma, I. (6) 419–424
- Radhakrishna, S., see Benson, C.S. (6) 395–405
- Ragazzi, E., see Agostini, M. (4) 269–278
- Rahimi, Z., see Rahimi, Z. (6) 437–443
- Rahimi, Z., Z. Rahimi, F. Shahvaisi-Zadeh, S. Sadeghei, M. Vessal and N. Yavari, eNOS 4a/b polymorphism and its interaction with eNOS G894T variants in type 2 diabetes mellitus: Modifying the risk of diabetic nephropathy (6) 437–443
- Rakowski, T., see Kleczyński, P. (3) 199–204
- Rallidis, L.S., see Zigra, A.-M. (6) 431–436
- Ravnik-Glavač, M., see Hrašovec, S. (2) 93–104
- Raya, A., see Palma, I. (6) 419–424
- Reiner-Concin, A., see Buxhofer-Ausch, V. (3) 171–177
- Reis, F., see Palavra, F. (5) 341–348
- Reséndez-Pérez, D., see Mar-Aguilar, F. (3) 163–169
- Rodríguez-Berrocal, F.J., see Sánchez-Otero, N. (6) 425–430
- Rodríguez-Padilla, C., see Mar-Aguilar, F. (3) 163–169
- Romero, M., see Palma, I. (6) 419–424
- Rothman, N., see Wu, S.-H. (4) 279–293
- Ruiz-Flores, P., see Mar-Aguilar, F. (3) 163–169
- Sabir, M., see Baig, R.M. (2) 71–80
- Sadeghei, S., see Rahimi, Z. (6) 437–443
- Sadeghi, M.R., see Lakpour, N. (3) 205–210
- Sakaguchi, Y., see Yamamoto, M. (3) 153–161
- Salama, R.H.M., H.A. Al-Shobaili, A.A. Al Robaee and A.A. Alzolibani, Psoriasis: A novel marker linked obesity with psoriasis (1) 33–39
- Sambuceti, G., see Ghigliotti, G. (2) 131–142
- Sancak, B., see Aydoğdu, M. (4) 237–246
- Sánchez-Otero, N., S. Blanco-Prieto, L. Vázquez-Iglesias, M.P. de la Cadena, A. Fernández-Villar, M.I. Botana-Rial and F.J. Rodríguez-Berrocal, Levels of PEDF in pleural effusions from lung adenocarcinoma and benign disease patients (6) 425–430
- Sankar, B.R., see Benson, C.S. (6) 395–405
- Santuario-Facio, S.K., see Mar-Aguilar, F. (3) 163–169
- Sari, G., see Aydoğdu, M. (4) 237–246
- Sassi Hannachi, S., see Ferchichi, I. (2) 63–69
- Schmid, M., see Kuessel, L. (1) 51–56
- Schuler-Faccini, L., see Boquett, J.A. (1) 41–49
- Selvamurugan, N., see Benson, C.S. (6) 395–405
- Serdaroğlu, E., see Nalbantoglu, S. (1) 23–32
- Sereno, J., see Palavra, F. (5) 341–348
- Serraglia, R., see Agostini, M. (4) 269–278
- Shahvaisi-Zadeh, F., see Rahimi, Z. (6) 437–443
- Shehata, H.H., see AbdRaboh, N.R. (6) 407–417
- Shetty, S., see Sukhtankar, L. (5) 305–311
- Shivaprasad, B.M. and A.R. Pradeep, Effect of non-surgical periodontal therapy on interleukin-29 levels in gingival crevicular fluid of chronic periodontitis and aggressive periodontitis patients (1) 1–7
- Shu, X.-O., see Wu, S.-H. (4) 279–293
- Singh, A., see Kathariya, R. (3) 143–151
- Singh, S., see Affandi, J.S. (6) 445–449
- Siudak, Z., see Kleczyński, P. (3) 199–204
- Šnez, M., see Aydoğdu, M. (4) 237–246
- Soria, J.M., see Baeza-Richer, C. (2) 121–129

- Spallarossa, P., see Ghigliotti, G. (2) 131–142
Spinella, G., see Ghigliotti, G. (2) 131–142
Sukhtankar, L., A. Kulloli, R. Kathariya and S. Shetty, Effect of non-surgical periodontal therapy on superoxide dismutase levels in gingival tissues of chronic periodontitis patients: A clinical and spectrophotometric analysis (5) 305–311
Sulik, A., see Korzeniecka-Kozerska, A. (5) 357–362
Sung, F.-C., see Li, Y.-F. (4) 247–255
Sung, F.-C., see Liu, C.-S. (3) 187–197
Surdacki, A., see Kleczyński, P. (3) 199–204
Szeto, C.-C., see Luk, C.C.-W. (3) 179–185
- Taşyürek, S., see Aydoğdu, M. (4) 237–246
Tabel, Y., see Nalbantoglu, S. (1) 23–32
Taheri, M. and F. Mahjoubi, MRP1 but not MDR1 is associated with response to neoadjuvant chemotherapy in breast cancer patients (6) 387–393
Teixeira, F., see Palavra, F. (5) 341–348
Teixeira-Lemos, E., see Palavra, F. (5) 341–348
Tenderenda, E., see Korzeniecka-Kozerska, A. (5) 357–362
Theodosiou, P., see Kanakis, D. (2) 81–91
Tóthová, L., see Kamodyová, N. (5) 313–321
Tóthová, L., V. Celecová and P. Celec, Salivary markers of oxidative stress and their relation to periodontal and dental status in children (1) 9–15
Traldi, P., see Agostini, M. (4) 269–278
Troudi, W., see Baccar, A. (5) 363–371
Tsai, M.-H., see Li, Y.-F. (4) 247–255
Tsai, Y.-C., see Lee, C.-T. (4) 229–235
Tural, S., see Inanir, A. (1) 17–22
Türk, M., see Aydoğdu, M. (4) 237–246
- Vaquero, M.P., see Baeza-Richer, C. (2) 121–129
Vázquez-Iglesias, L., see Sánchez-Otero, N. (6) 425–430
Vessal, M., see Rahimi, Z. (6) 437–443
- Wang, G., see Luk, C.C.-W. (3) 179–185
Wasilewska, A., see Korzeniecka-Kozerska, A. (5) 357–362
Wen, W., see Wu, S.-H. (4) 279–293
Wu, C.-H., see Lee, C.-T. (4) 229–235
Wu, N.-Q., see Qing, P. (5) 333–339
Wu, S.-H., X.-O. Shu, W.-H. Chow, Y.-B. Xiang, X. Zhang, Q. Cai, H.-L. Li, G. Milne, W. Wen, B.-T. Ji, N. Rothman, Y.-T. Gao, W. Zheng and G. Yang, Adiposity and fat distribution in relation to inflammation and oxidative stress in a relatively lean population of Chinese women (4) 279–293
Wu, Y., see He, J. (6) 379–386
- Xiang, Y.-B., see Wu, S.-H. (4) 279–293
Xu, R.-X., see Qing, P. (5) 333–339
- Yamamoto, M., Y. Imai, Y. Sakaguchi, T. Haneda and K. Yamanishi, Serum cytokines correlated with the disease severity of generalized pustular psoriasis (3) 153–161
Yamanishi, K., see Yamamoto, M. (3) 153–161
Yang, G., see Wu, S.-H. (4) 279–293
Yavari, N., see Rahimi, Z. (6) 437–443
Ye, X., see Feng, G. (2) 105–111
Yeh, C.-C., see Li, Y.-F. (4) 247–255
Yeh, C.-C., see Liu, C.-S. (3) 187–197
Yeni, S., see Aydoğdu, M. (4) 237–246
Yigit, S., see Inanir, A. (1) 17–22
Yildirim, E., see Inanir, A. (1) 17–22
Yüksel, S., see Aydoğdu, M. (4) 237–246
- Zdzienicka, J., see Kleczyński, P. (3) 199–204
Zeillinger, R., see Buxhofer-Ausch, V. (3) 171–177
Zhang, B., see Jiang, Z.-L. (5) 295–304
Zhang, F., see He, J. (6) 379–386
Zhang, W., see He, J. (6) 379–386
Zhang, W., see He, J. (6) 379–386
Zhang, X., see Wu, S.-H. (4) 279–293
Zhao, Y., see He, J. (6) 379–386
Zhao, Y., see He, J. (6) 379–386
Zheng, D., see Cai, A. (5) 323–331
Zheng, W., see Wu, S.-H. (4) 279–293
Zhou, Y., see Cai, A. (5) 323–331
Zhu, C.-G., see Qing, P. (5) 333–339
Zhu, X., see He, J. (6) 379–386
Zigra, A.-M., L.S. Rallidis, G. Anastasiou, E. Merkouri and A. Gialeraki, eNOS gene variants and the risk of premature myocardial infarction (6) 431–436